
Release date: 2024-07-09 15:52:53 Article From: Lucius Laos Recommended: 739
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appointed by the World Health Organization (WHO) and director of the Microbiology Laboratory of the National Institute for Drug Control of Portugal, made an important technical support visit to the Lucius pharmaceutical factory in Laos.

This visit is an important opportunity for academic exchange and cooperation. The chairman of Lucius Pharmaceuticals personally met with Dr. Louis, and the two sides had in-depth communication on further academic exchanges and cooperation.
During his visit, Dr. Luis trained Lucius and those participating in the World Health Organization (WHO) laboratory pre-accreditation. He gave a detailed account of the requirements, experience and progress of the Portuguese National Institute for Drug Control, as well as the World Health Organization (WHO) for the prequalification of microbiological and sterile laboratories. He also shared the experience of the Portuguese National Institute for Drug Control in 2011 to achieve precertification.

This visit not only strengthened the academic exchanges and cooperation between the two countries in the field of microbiology, but also provided valuable technical support and guidance for the Lucius Pharmaceutical Factory in Laos. This is a landmark visit that is of great significance for the development of global public health.

In addition, the visit also marked the enhancement of Lucius Pharmaceuticals' position in the field of global public health. Not only have they received technical support from Dr. Luís Meirinhos Soares, Director of the Microbiology Laboratory at the National Institute for Drug Control in Portugal, but they have also been recognized by the World Health Organization (WHO).
This recognition is an affirmation of Lucius Pharmaceutical's expertise and rigorous attitude in the field of microbial testing and testing. They have always insisted on using state-of-the-art technology and equipment to ensure the quality and safety of their products. In addition, they actively participate in various academic exchanges and collaborations to improve their R&D capabilities and technical level.

This recognition is also a recognition of the hard work and professionalism of the employees of Lucius Pharma Laos who have always been people-oriented and focused on the professional development and welfare of their employees. They believe that only satisfied employees can provide quality products and services.
This recognition is a recognition of Lucius Pharma's contribution to the global public health field We look forward to their continued efforts in the future and their greater role in global public health.
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed countries (extended to July 1, 2033), Laos has been legally permitted to produce ge···【more】
Recommended:219Release date: 2026-08-05
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos have gradually entered the view of Chinese cancer and chronic disease patients due ···【more】
Recommended:230Release date: 2026-08-04
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rapid growth in its generic pharmaceutical industry in recent years. Lucius Pharmac···【more】
Recommended:271Release date: 2026-07-31
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital of Laos. The company was established in 2020, with its R&D and operational s···【more】
Recommended:203Release date: 2026-07-28
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Drug CompanyRelocation Background and Strategic ShiftLucius Pharmaceuticals was fo···【more】
Recommended:305Release date: 2026-07-24
In recent years, Laos has gradually become a major global supply source for generic drugs, leveraging the WTO-granted patent exemption for least-developed countries. Among them, Lu···【more】
Recommended:242Release date: 2026-07-22
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was established in 2020, with its headquarters located at No. 26, Thongmang Village···【more】
Recommended:258Release date: 2026-07-20
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended:274Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended:380Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended:229Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended:298Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended:324Release date: 2026-07-09
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended:924Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended:865Release date: 2024-07-09
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic name: vibegron) is an oral, once-daily β3-adrenergic receptor agonist approved by ···【more】
Recommended:174Release date: 2026-08-06
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 previously untreated CLL/SLL patients aged 65 years and older, ibrutinib demonst···【more】
Recommended:186Release date: 2026-08-03
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the class of ALK inhibitors. Unlike traditional chemotherapy, it does not act by kill···【more】
Recommended:167Release date: 2026-07-30
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet. The recommended dose is once daily, one tablet per day (the specific dose is de···【more】
Recommended:196Release date: 2026-07-29
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies for DacomitinibRash and exfoliative skin reactions are highly characteristic adv···【more】
Recommended:207Release date: 2026-07-21
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these con···【more】
Recommended:198Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an oral anticancer drug whose active ingredient is pirtobrutinib, belonging to the class of Bruton's···【more】
Recommended:227Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name LuciElag) for the treatment of moderate to severe pain associated with endometr···【more】
Recommended:250Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated in the following situations: ①hypersensitivity to bempedoic acid or any excipient···【more】
Recommended:218Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegromab, through its selective inhibition of myostatin, can maintain lean body mass wh···【more】
Recommended:254Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Recommended:349Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Recommended:685Release date: 2025-12-17

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643